Solid Biosciences (SLDB) Cash & Equivalents (2017 - 2026)

Solid Biosciences has disclosed Cash & Equivalents across 10 years of filings, most recently posting $297.1 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $297.1 million, up 41.05% year-over-year; the trailing twelve-month figure through Mar 2026 was $297.1 million (up 41.05% YoY), and the FY2025 annual result was $59.9 million, down 25.34% from the prior year.
• Cash & Equivalents came in at $297.1 million for Q1 2026 at Solid Biosciences, up from $59.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $297.1 million in Q1 2026 to a low of $48.8 million in Q3 2022.
• The 5-year median for Cash & Equivalents is $91.6 million (2023), against an average of $111.4 million.
• Across the five-year window, Cash & Equivalents sank 72.93% in 2022 and jumped 79.15% in 2025, its largest moves.
• Solid Biosciences' Cash & Equivalents stood at $155.4 million in 2022, then sank by 52.37% to $74.0 million in 2023, then climbed by 8.4% to $80.2 million in 2024, then dropped by 25.34% to $59.9 million in 2025, then surged by 395.99% to $297.1 million in 2026.
• The last three Cash & Equivalents figures came in at $297.1 million (Q1 2026), $59.9 million (Q4 2025), and $61.4 million (Q3 2025), per Business Quant data.